What does DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE do?

DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is a general practice in Brussel. Private Limited, started on 31 May 2011, 2 establishments.

What is the address of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE?

The registered office of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is located at Nieuwe Graanmarkt 13, 1000 Brussel.

Is DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE still active?

Yes. According to the CBE (5 October 2026) DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is active, legal situation “Normale toestand”, started on 31 May 2011.

Is DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE registered on Peppol?

Yes, DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is registered on the Peppol network with ID 0208:0836671322.

What is the enterprise number of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE?

The enterprise number of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is BE0836671322.

When was DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE founded?

DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE was founded on 31 May 2011.

Who are the directors of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE?

According to the 2024 annual accounts, the directors of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE are: Refat SHARAFEDIN.

Is DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 May 2011; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE make in 2024?

DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE posted a profit after taxes of € 119,664 in financial year 2024.

What is the revenue of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE?

As a small company, DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 355,557.

DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE (Private Limited)

Dossier DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE, printed on 5 October 2026 from databakkes.be/en/0836671322/dr-refat-sharafedin-algemene-geneeskunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE from Brussel, company number BE0836671322, closed financial year 2024 with a result of € 119,664 after tax. For that financial year DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE recorded a gross margin of € 355,557 and equity of € 659,800. Compared with financial year 2023, the result moved from € 117,062 to € 119,664. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 31, 2025.

What it is worth Growing

€ 659,800

▲ 3% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 119,664

▲ 2% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 331,425

▲ 81% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 100,834 paid out

84 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2024

Wage cost

€ 66,246

▲ 16% vs 2023

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 73,478

▼ 32% vs 2023

Of which on lease € 66,025.

Debts at end 2024

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 343,939

▼ 15% vs 2023

€ 59,933 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 347

▼ 72% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 30,912

▼ 32% vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 344,863 Gross margin 2021: € 344,863 First fiscal year in the series	€ 305,660 Gross margin 2022: € 305,660 ▼ 11% vs 2021 (€ 344,863) Unfavourable step	€ 369,308 Gross margin 2023: € 369,308 ▲ 21% vs 2022 (€ 305,660) Favourable step	€ 355,557 Gross margin 2024: € 355,557 ▼ 4% vs 2023 (€ 369,308) Unfavourable step	▼ 4%
Profit after taxes	€ 158,071 Profit after taxes 2021: € 158,071 First fiscal year in the series	€ 118,709 Profit after taxes 2022: € 118,709 ▼ 25% vs 2021 (€ 158,071) Unfavourable step	€ 117,062 Profit after taxes 2023: € 117,062 ▼ 1% vs 2022 (€ 118,709) Unfavourable step	€ 119,664 Profit after taxes 2024: € 119,664 ▲ 2% vs 2023 (€ 117,062) Favourable step	▲ 2%
Equity	€ 613,226 Equity 2021: € 613,226 First fiscal year in the series	€ 638,867 Equity 2022: € 638,867 ▲ 4% vs 2021 (€ 613,226) Favourable step	€ 640,969 Equity 2023: € 640,969 Unchanged (€ 638,867) Favourable step	€ 659,800 Equity 2024: € 659,800 ▲ 3% vs 2023 (€ 640,969) Favourable step	▲ 3%
Total debts	€ 531,918 Total debts 2021: € 531,918 First fiscal year in the series	€ 552,717 Total debts 2022: € 552,717 ▲ 4% vs 2021 (€ 531,918) Unfavourable step	€ 563,967 Total debts 2023: € 563,967 ▲ 2% vs 2022 (€ 552,717) Unfavourable step	€ 476,157 Total debts 2024: € 476,157 ▼ 16% vs 2023 (€ 563,967) Favourable step	▼ 16%
Cash	€ 338,355 Cash 2021: € 338,355 First fiscal year in the series	€ 484,156 Cash 2022: € 484,156 ▲ 43% vs 2021 (€ 338,355) Favourable step	€ 183,459 Cash 2023: € 183,459 ▼ 62% vs 2022 (€ 484,156) Unfavourable step	€ 331,425 Cash 2024: € 331,425 ▲ 81% vs 2023 (€ 183,459) Favourable step	▲ 81%
Land & buildings	€ 507,670 Land & buildings 2021: € 507,670 First fiscal year in the series	€ 459,717 Land & buildings 2022: € 459,717 ▼ 9% vs 2021 (€ 507,670) Unchanged	€ 685,137 Land & buildings 2023: € 685,137 ▲ 49% vs 2022 (€ 459,717) Unchanged	€ 630,173 Land & buildings 2024: € 630,173 ▼ 8% vs 2023 (€ 685,137) Unchanged	▼ 8%
Retained profit	€ 600,826 Retained profit 2021: € 600,826 First fiscal year in the series	€ 626,467 Retained profit 2022: € 626,467 ▲ 4% vs 2021 (€ 600,826) Favourable step	€ 628,569 Retained profit 2023: € 628,569 Unchanged (€ 626,467) Favourable step	€ 647,400 Retained profit 2024: € 647,400 ▲ 3% vs 2023 (€ 628,569) Favourable step	▲ 3%
Dividend	€ 53,485 Dividend 2021: € 53,485 First fiscal year in the series	€ 93,068 Dividend 2022: € 93,068 ▲ 74% vs 2021 (€ 53,485) Unchanged	€ 114,960 Dividend 2023: € 114,960 ▲ 24% vs 2022 (€ 93,068) Unchanged	€ 100,834 Dividend 2024: € 100,834 ▼ 12% vs 2023 (€ 114,960) Unchanged	▼ 12%
Bank debt	€ 436,477 Bank debt 2021: € 436,477 First fiscal year in the series	€ 388,025 Bank debt 2022: € 388,025 ▼ 11% vs 2021 (€ 436,477) Favourable step	€ 402,543 Bank debt 2023: € 402,543 ▲ 4% vs 2022 (€ 388,025) Unfavourable step	€ 343,939 Bank debt 2024: € 343,939 ▼ 15% vs 2023 (€ 402,543) Favourable step	▼ 15%
Balance sheet total	€ 1,145,144 Balance sheet total 2021: € 1,145,144 First fiscal year in the series	€ 1,191,584 Balance sheet total 2022: € 1,191,584 ▲ 4% vs 2021 (€ 1,145,144) Unchanged	€ 1,204,936 Balance sheet total 2023: € 1,204,936 ▲ 1% vs 2022 (€ 1,191,584) Unchanged	€ 1,135,957 Balance sheet total 2024: € 1,135,957 ▼ 6% vs 2023 (€ 1,204,936) Unchanged	▼ 6%

Key figures of DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE?

What happened at DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 31, 2025 New annual accounts for financial year 2024: profit of € 119,664 (▲ 2% vs 2023). filed late Source: NBB ↗
May 14, 2021 New establishment in Sint-Jans-Molenbeek. KBO
Jul 1, 2011 New establishment in Brussel. KBO
May 31, 2011 Start of the company according to the CBE. KBO

In short

From € 158,071 profit in 2021 to € 119,664 profit in 2024.

Paid € 225,120 in corporate taxes since 2021.

Best year ever: 2021, with € 158,071 profit.

Paid out € 362,347 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE? We notify you, reason included.

Follow DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Refat SHARAFEDIN

DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE

Behind DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE is Refat SHARAFEDIN.

See the full network in the app

Directors

According to the 2024 annual accounts

Refat SHARAFEDIN

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Nieuwe Graanmarkt 13

1000 Brussel

2.317.127.486

Jean-Baptiste Decockstraat 21

1080 Sint-Jans-Molenbeek

Active since 14 May 2021

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0836.671.322
VAT number: BE 0836.671.322
Registered office: Nieuwe Graanmarkt 13, 1000 Brussel
Names & denominations: DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 31 May 2011
Peppol: Active · Active since 17 Jun 2026
Activities · NACE: Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗